Results 21 to 30 of about 64,429 (258)

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters

ESC Heart Failure, 2022
Aims To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. Methods and results Seventy‐two women with breast cancer (52 ± 
Belén Díaz‐Antón, Rodrigo Madurga, Blanca Zorita, Samantha Wasniewski, Andrea Moreno‐Arciniegas, Beatriz López‐Melgar, Natalia Ramírez Merino, Roberto Martín‐Asenjo, Patricia Barrio, Maximiliano German Amado Escañuela, Jorge Solís, Francisco Javier Parra Jiménez, Eva Ciruelos, José María Castellano, Leticia Fernández‐Friera   +14 more
doaj   +1 more source

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis

Frontiers in Immunology, 2022
Immune checkpoint inhibitors (ICIs) in combination withother anti-cancer treatments have been approved for a variety of cancers. While the difference in the incidence of cardiovascular adverse events has not been fully investigated.
Maobai Liu, Maobai Liu, Xitong Cheng, Xitong Cheng, Ruping Ni, Ruping Ni, Bin Zheng, Bin Zheng, Shunmin Huang, Shunmin Huang, Jing Yang, Jing Yang   +11 more
doaj   +1 more source

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

Frontiers in Oncology
ObjectiveTo investigate the risk factors associated with cardiotoxicity in patients with non-small cell lung cancer (NSCLC) treated with osimertinib.MethodsA total of 268 patients with NSCLC treated with osimertinib in our hospital from June 2019 to ...
Yunlong Wang, Xuan Deng, Qinggui Qiu, Mengchao Wan   +3 more
doaj   +1 more source

Cardiotoxicity: an adverse effect of chemotherapy

, 2021
Cardiotoxicity of cancer chemotherapy drugs is a challenge for oncologists and patients. This thesis summarizes the toxic effects of some chemotherapy drugs. It talks about the pathomechanisms of the different drugs and about the epidemiology.
Banjoko, Olatunbosun Ganihu
core  

Paclitaxel-induced Cardiotoxicity: Mechanisms, Molecular Insights, and Clinical Implications [PDF]

Archives of Pharmaceutical Sciences Ain Shams University
Paclitaxel is a well-known chemotherapeutic agent used to treat various cancers, including breast, lung, and pancreatic cancers. However, its effectiveness is limited by significant adverse effects, including neurotoxicity, nephrotoxicity, hepatotoxicity,
El-Nagar, Yasmine M., George, Mina Y., El Wakeel, Sara, Elsherbiny, Doaa A.   +3 more
doaj   +1 more source

Risk Compounds, Preclinical Toxicity Evaluation, and Potential Mechanisms of Chinese Materia Medica–Induced Cardiotoxicity

Frontiers in Pharmacology, 2021
Chinese materia medica (CMM) has been applied for the prevention and treatment of diseases for thousands of years. However, arrhythmia, myocardial ischemia, heart failure, and other cardiac adverse reactions during CMM application were gradually reported.
Jie Zhou, Jie Zhou, Jie Zhou, Fu Peng, Xiaoyu Cao, Xiaoyu Cao, Xiaofang Xie, Xiaofang Xie, Dayi Chen, Lian Yang, Chaolong Rao, Cheng Peng, Cheng Peng, Xiaoqi Pan, Xiaoqi Pan   +14 more
doaj   +1 more source

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Acta Oncologica
Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF).
Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis   +5 more
doaj   +1 more source

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs

Frontiers in Oncology
Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive.
Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng   +4 more
doaj   +1 more source

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

Frontiers in Pharmacology, 2020
Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA.
Ying Jin, Zhifei Xu, Hao Yan, Qiaojun He, Xiaochun Yang, Peihua Luo   +5 more
doaj   +1 more source

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

Frontiers in Cardiovascular Medicine, 2022
The development of various antitumor drugs has significantly improved the survival of patients with cancer. Many first-line chemotherapy drugs are cytotoxic and the cardiotoxicity is one of the most significant effects that could leads to poor prognosis ...
Wei Huang, Rong Xu, Bin Zhou, Chao Lin, Yingkun Guo, Huayan Xu, Xia Guo   +6 more
doaj   +1 more source